Literature DB >> 1822318

Analgesic effect of L-arginine in patients with persistent pain.

A Harima1, H Shimizu, H Takagi.   

Abstract

Our previous pharmacological studies using animals indicated that a systemic administration of L-arginine induces an antinociceptive effect and an increase in the brain level of kyotorphin (L-tyrosinyl-L-arginine) which is an endogenous analgesic peptide and a methionine-enkephalin releaser in the brain. The aims of this study were to investigate the analgesic effect of L-arginine, a precursor of kyotorphin, in persistent pain. We selected 12 patients with various kinds of pain of at least 6 months duration. L-Arginine (10% solution, 300 ml (30 g)/patient) was administered by intravenous drip at a rate of 5 ml (0.5 g)/min during a period of 60-70 min. Pain was assessed by the patient using a 10-cm visual analogue scale (VAS), before and after the L-arginine infusion. L-Arginine treatment resulted in slight analgesia at 10-15 min after the onset of infusion and in marked analgesia at 30-40 min after that. This effect lasted for 6-24 h. L-Arginine-induced analgesia was dose-dependent and blocked by intravenous injection of naloxone. In each case, the L-arginine-induced analgesia was statistically significant as compared with the saline-induced effect. Side effects of L-arginine were a slight decrease in mean blood pressure (10-15 mm Hg), and dryness of the month. A suppressive role of a functional link between the L-arginine-kyotorphin system and the enkephalin system of the brain in persistent pain is suggested.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1822318     DOI: 10.1016/0924-977x(91)90006-g

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  9 in total

1.  L-Arginine supplementation prevents allodynia and hyperalgesia in painful diabetic neuropathic rats by normalizing plasma nitric oxide concentration and increasing plasma agmatine concentration.

Authors:  Lusliany J Rondón; M C Farges; N Davin; B Sion; A M Privat; M P Vasson; A Eschalier; C Courteix
Journal:  Eur J Nutr       Date:  2017-07-19       Impact factor: 5.614

2.  Comparison of antinociception induced by supraspinally administered L-arginine and kyotorphin.

Authors:  A Kawabata; S Manabe; H Takagi
Journal:  Br J Pharmacol       Date:  1994-07       Impact factor: 8.739

3.  L-arginine exerts a dual role in nociceptive processing in the brain: involvement of the kyotorphin-Met-enkephalin pathway and NO-cyclic GMP pathway.

Authors:  A Kawabata; N Umeda; H Takagi
Journal:  Br J Pharmacol       Date:  1993-05       Impact factor: 8.739

4.  L-leucyl-L-arginine, naltrindole and D-arginine block antinociception elicited by L-arginine in mice with carrageenin-induced hyperalgesia.

Authors:  A Kawabata; Y Nishimura; H Takagi
Journal:  Br J Pharmacol       Date:  1992-12       Impact factor: 8.739

5.  Pressor, renal and endocrine effects of L-arginine in essential hypertensives.

Authors:  R Pedrinelli; M Ebel; G Catapano; G Dell'Omo; M Ducci; M Del Chicca; A Clerico
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

6.  The noradrenaline precursor L-threo-3,4-dihydroxyphenylserine exhibits antinociceptive activity via central alpha-adrenoceptors in the mouse.

Authors:  A Kawabata; K Kasamatsu; N Umeda; H Takagi
Journal:  Br J Pharmacol       Date:  1994-02       Impact factor: 8.739

7.  Activation of the cGMP/Protein Kinase G Pathway by Nitric Oxide Can Decrease TRPV1 Activity in Cultured Rat Dorsal Root Ganglion Neurons.

Authors:  Yunju Jin; Jun Kim; Jiyeon Kwak
Journal:  Korean J Physiol Pharmacol       Date:  2012-06-26       Impact factor: 2.016

Review 8.  Pharmacological Potential of the Endogenous Dipeptide Kyotorphin and Selected Derivatives.

Authors:  Juliana Perazzo; Miguel A R B Castanho; Sónia Sá Santos
Journal:  Front Pharmacol       Date:  2017-01-12       Impact factor: 5.810

Review 9.  The role of the arginine metabolome in pain: implications for sickle cell disease.

Authors:  Nitya Bakshi; Claudia R Morris
Journal:  J Pain Res       Date:  2016-03-30       Impact factor: 3.133

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.